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Purpose of the study
The Phase III TITAN trial (TMC114-C214) evaluated daru-
navir/ritonavir (DRV/r) 600/100 mg BID vs. lopinavir/
ritonavir (LPV/r) 400/100 mg BID in treatment-experi-
enced, LPV/r-naïve, HIV-infected adults. We determined
the cost-effectiveness of DRV/r vs. LPV/r from the perspec-
tive of British, Swedish, Italian and Belgian payers in the
TITAN trial subgroup with at least one IAS-USA primary
protease inhibitor (PI) mutation at baseline. These
patients had less advanced HIV disease and a broader
degree of prior PI use/failure (0- ≥2) than those in the
DRV Phase IIb POWER trials (≥2).
Methods
An existing Markov model containing six CD4+ T-cell
count (CD4 count)-defined health states and a "death"
state was adapted to the above mentioned countries. Base-
line demographics and CD4 count distribution, antiretro-
viral drug usage, virologic and immunologic response
rates and matching transition probabilities were based on
TITAN trial data collected in the modelled subgroup dur-
ing the first 48 weeks of therapy and from published liter-
ature. Patients were assumed to switch to a follow-up
combination therapy after failure. For each model state,
utility values and mortality rates were obtained from pub-
lished literature. Costs in each state were obtained from
local observational studies and official, local unit costs or
from published literature. A lifetime horizon was taken.
Discount rates varied according to local guidelines.
Summary of results
The base-case incremental cost-utility was €18,213
(£13,111)/QALY, €7,605 (SEK 70,379)/QALY, €17,592/
QALY and €7,990/QALY in the UK, Sweden, Italy and Bel-
gium, respectively. Assuming a threshold of €30,000/
QALY, DRV/r remained cost-effective over most parame-
ter ranges tested in extensive one-way sensitivity analyses.
Probabilistic sensitivity analysis revealed a probability of
≥67% of an ICER below this threshold in all countries.
Conclusion
From the British, Swedish, Italian and Belgian payer per-
spective, DRV/r 600/100 mg BID is predicted to be cost-
effective vs. LPV/r in the management of LPV/r-naïve, PI-
resistant, HIV-infected adults with a broad range of prior
PI use/failure.
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